Barrow, Hanley, Mewhinney & Strauss
ANIP icon

Barrow, Hanley, Mewhinney & Strauss’s ANI Pharmaceuticals ANIP Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,593
Closed -$213K – 317
2020
Q2 		$213K Buy
+6,593
New +$236K ﹤0.01% 287

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's ANIP Position: Q3 2020 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of ANI Pharmaceuticals (ANIP) in Q3 2020, closing a stake of 6,593 shares — an estimated $213K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in ANIP in Q2 2020 and held it in 1 quarter. The position peaked at $213K in Q2 2020. 116 funds tracked by Wall St. Rank hold ANIP as of Q3 2020.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining ANI Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 6,593 ANI Pharmaceuticals shares in Q3 2020, an estimated $213K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in ANI Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Barrow, Hanley, Mewhinney & Strauss's ANI Pharmaceuticals position peaked at $213K in Q2 2020.
  • 116 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2020.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q3 2020, filed 12 Nov 2020.